These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8202716)

  • 1. Total platinum dose versus platinum dose intensification in ovarian cancer treatment.
    Alberts DS; Garcia DJ
    Semin Oncol; 1994 Apr; 21(2 Suppl 2):11-5; quiz 16, 58. PubMed ID: 8202716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
    Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):19-24. PubMed ID: 15726535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
    Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma.
    Strauss G; Lund B; Hansen M; Hansen HH
    Gynecol Oncol; 1997 Jul; 66(1):66-70. PubMed ID: 9234923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
    Markman M; Markman J; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
    J Clin Oncol; 2004 Aug; 22(15):3120-5. PubMed ID: 15284263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of advanced ovarian cancer.
    Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
    Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
    Orr JW; Orr P; Kern DH
    Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
    Saldivar JS; Wu X; Follen M; Gershenson D
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.
    Markman M; Lichtman SM; Homesley H; Kennedy A; Webster K; Ernst S; Omura G; Belinson J
    Gynecol Oncol; 1998 Jul; 70(1):123-6. PubMed ID: 9698488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.